In contrast to CD11b, the surface expression of CD162 tended to be lower in the patients with COVID-19 (581.6 ± 224.2 AU) than in the patient controls (821.1 ± 242.3 AU; CI, −488.5 to 9.4; P = .06) or healthy subjects (722.3 ± 124.3 AU; CI, −389.7 to 108.2; P = .48). Here, ITGAM is linked to COVID-19.